Study aim: Determining the effectiveness of silymarin in patients with inflammatory bowel disease Design: Clinical trial with a control group, parallel groups, double-blind, randomized, phase 3, on 40 patients. The randomization will be done by the random number table method through the website http//www.graphpad.com/quickcalcs/index.cfm. Settings and conduct: This study will be conducted with the aim of determining the efficacy of silymarin in children suffering from inflammatory bowel disease in Akbar Mashhad Hospital. In the intervention group, silymarin tablets (Gol Daru Company) with a dose of 5 mg per kilogram in divided doses three times a day for three months will be used daily, and in the control group, a placebo will be used, similar to the intervention group. Disease symptoms will be evaluated at the beginning and end of the intervention through a questionnaire. This study is double-blind, the patients and those who evaluate the outcome are unaware of the type of drug received. Participants/Inclusion and exclusion criteria: Inclusion criteria: Inflammatory bowel disease Exclusion criteria: The patient's unwillingness to visit the gastroenterology clinic regularly for regular examinations and check-ups Intervention groups: Intervention group: Silymarin tablets (Gol Daro Company) with a dose of 5 mg/kg in divided doses three times a day for three months on a daily basis. Control group: Three times a day placebo for three months on a daily basis Main outcome variables: The main outcome variable will be inflammatory bowel disease symptoms.